CASI Pharmaceuticals appoints Rong Chen as chief medical officer

Oncology biopharma company CASI Pharmaceuticals (Nasdaq: CASI) has appointed Rong Chen as chief medical officer.

Dr Chen brings more than 20 years of pharma development and regulatory affairs, and joins from GlaxoSmithKline (LSE: GSK) where he was most recently head of regulatory center of excellence, having overall responsibility for the registration of drug and vaccine products. Prior to his roles at GSK, he was medical director at Bayer-Schering Pharma for the Asia Pacific area.

Ken Ren, CASI's chief executive, said: "We are very pleased that Dr Chen joins CASI as Chief Medical Officer adding his invaluable medical and regulatory experience and expertise to our growing management team. Dr Chen brings a strong and successful track record in new drug development and pipeline enrichment in a variety of different therapeutic areas particularly in oncology. He will lead our clinical and regulatory activities in both North America and greater China and will contribute to the expansion of our product pipeline through our dual development strategy of acquisition and internal development."